Cargando…
Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an effective new vaccine is urgently needed. A major barrier to the rational development of novel TB vaccines is the lack of a validated immune correlate or biomarker of protection. Mycobacterial Growth Inhibition Assays...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968127/ https://www.ncbi.nlm.nih.gov/pubmed/31998295 http://dx.doi.org/10.3389/fimmu.2019.02983 |
_version_ | 1783489077439365120 |
---|---|
author | Tanner, Rachel Satti, Iman Harris, Stephanie A. O'Shea, Matthew K. Cizmeci, Deniz O'Connor, Daniel Chomka, Agnieszka Matsumiya, Magali Wittenberg, Rachel Minassian, Angela M. Meyer, Joel Fletcher, Helen A. McShane, Helen |
author_facet | Tanner, Rachel Satti, Iman Harris, Stephanie A. O'Shea, Matthew K. Cizmeci, Deniz O'Connor, Daniel Chomka, Agnieszka Matsumiya, Magali Wittenberg, Rachel Minassian, Angela M. Meyer, Joel Fletcher, Helen A. McShane, Helen |
author_sort | Tanner, Rachel |
collection | PubMed |
description | Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an effective new vaccine is urgently needed. A major barrier to the rational development of novel TB vaccines is the lack of a validated immune correlate or biomarker of protection. Mycobacterial Growth Inhibition Assays (MGIAs) provide an unbiased measure of ability to control mycobacterial growth in vitro, and may represent a functional correlate of protection. However, the biological relevance of any potential correlate can only be assessed by determining the association with in vivo protection from either a controlled mycobacterial infection or natural development of TB disease. Our data demonstrate that the direct MGIA using peripheral blood mononuclear cells (PBMC) is measuring a biologically relevant response that correlates with protection from in vivo human BCG infection across two independent cohorts. This is the first report of an MGIA correlating with in vivo protection in the species-of-interest, humans, and furthermore on a per-individual as well as per-group basis. Control of mycobacterial growth in the MGIA is associated with a range of immune parameters measured post-BCG infection in vivo including the IFN-γ ELISpot response, frequency of PPD-specific IFN-γ or TNF-α producing CD4+ T cells and frequency of specific sub-populations of polyfunctional CD4+ T cells. Distinct transcriptomic profiles are associated with good vs. poor mycobacterial control in the MGIA, with good controllers showing enrichment for gene sets associated with antigen processing/presentation and the IL-23 pathway, and poor controllers showing enrichment for hypoxia-related pathways. This study represents an important step toward biologically validating the direct PBMC MGIA for use in TB vaccine development and furthermore demonstrates the utility of this assay in determining relevant immune mechanisms and pathways of protection. |
format | Online Article Text |
id | pubmed-6968127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69681272020-01-29 Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection Tanner, Rachel Satti, Iman Harris, Stephanie A. O'Shea, Matthew K. Cizmeci, Deniz O'Connor, Daniel Chomka, Agnieszka Matsumiya, Magali Wittenberg, Rachel Minassian, Angela M. Meyer, Joel Fletcher, Helen A. McShane, Helen Front Immunol Immunology Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an effective new vaccine is urgently needed. A major barrier to the rational development of novel TB vaccines is the lack of a validated immune correlate or biomarker of protection. Mycobacterial Growth Inhibition Assays (MGIAs) provide an unbiased measure of ability to control mycobacterial growth in vitro, and may represent a functional correlate of protection. However, the biological relevance of any potential correlate can only be assessed by determining the association with in vivo protection from either a controlled mycobacterial infection or natural development of TB disease. Our data demonstrate that the direct MGIA using peripheral blood mononuclear cells (PBMC) is measuring a biologically relevant response that correlates with protection from in vivo human BCG infection across two independent cohorts. This is the first report of an MGIA correlating with in vivo protection in the species-of-interest, humans, and furthermore on a per-individual as well as per-group basis. Control of mycobacterial growth in the MGIA is associated with a range of immune parameters measured post-BCG infection in vivo including the IFN-γ ELISpot response, frequency of PPD-specific IFN-γ or TNF-α producing CD4+ T cells and frequency of specific sub-populations of polyfunctional CD4+ T cells. Distinct transcriptomic profiles are associated with good vs. poor mycobacterial control in the MGIA, with good controllers showing enrichment for gene sets associated with antigen processing/presentation and the IL-23 pathway, and poor controllers showing enrichment for hypoxia-related pathways. This study represents an important step toward biologically validating the direct PBMC MGIA for use in TB vaccine development and furthermore demonstrates the utility of this assay in determining relevant immune mechanisms and pathways of protection. Frontiers Media S.A. 2020-01-10 /pmc/articles/PMC6968127/ /pubmed/31998295 http://dx.doi.org/10.3389/fimmu.2019.02983 Text en Copyright © 2020 Tanner, Satti, Harris, O'Shea, Cizmeci, O'Connor, Chomka, Matsumiya, Wittenberg, Minassian, Meyer, Fletcher and McShane. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Tanner, Rachel Satti, Iman Harris, Stephanie A. O'Shea, Matthew K. Cizmeci, Deniz O'Connor, Daniel Chomka, Agnieszka Matsumiya, Magali Wittenberg, Rachel Minassian, Angela M. Meyer, Joel Fletcher, Helen A. McShane, Helen Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection |
title | Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection |
title_full | Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection |
title_fullStr | Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection |
title_full_unstemmed | Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection |
title_short | Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection |
title_sort | tools for assessing the protective efficacy of tb vaccines in humans: in vitro mycobacterial growth inhibition predicts outcome of in vivo mycobacterial infection |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968127/ https://www.ncbi.nlm.nih.gov/pubmed/31998295 http://dx.doi.org/10.3389/fimmu.2019.02983 |
work_keys_str_mv | AT tannerrachel toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection AT sattiiman toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection AT harrisstephaniea toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection AT osheamatthewk toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection AT cizmecideniz toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection AT oconnordaniel toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection AT chomkaagnieszka toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection AT matsumiyamagali toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection AT wittenbergrachel toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection AT minassianangelam toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection AT meyerjoel toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection AT fletcherhelena toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection AT mcshanehelen toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection |